Up next I am going to go through the CodeBreaK100 trial, evaluating AMG510 in patients with KRAS G12C+ NSCLC. I know a lot of people have already gone over these data, but here we go! #LCSM #WCLC20

To recap, sotorasib (nee AMG510) is an allosteric inhibitor of KRAS via a new pocket made by the G12C mutation. This Phase 2 trial evaluated the drug in patients with KRAS G12C+ NSCLC that had experienced disease progression on prior therapies. #LCSM #WCLC20

I know the ORR is not as good as alectinib or osimertinib, but this is really impressive to me. We have tried to target KRAS for years and have seen no activity. This is a great first step to help patients with NSCLC harboring this common alteration #WCLC20 #LCSM

The DOR was initially a concern after the Ph1 data, but to me this closely resembles what we saw for 1G inhibitors of EGFR and ALK. For the patients that benefit, this is a clearly active drug. The next step is to understand why more people don't benefit #WCLC20 #LCSM

One of the most confounding aspects of the G12C inhibitors is the fact that they seem to work pretty well in NSCLC, but have very little activity in CRC, pancreatic cancer, or other diseases with KRAS G12C as a driver. We need to understand this biology better! #LCSM #WCLC20

As we have seen before, the AE profile of sotorasib is pretty favorable. Most TRAE's are Gr1-2 and rare need for treatment discontinuation. I would be interested to know which AE's led to dose modification - hard to tell from this table #LCSM #WCLC20

Overall I am very excited about these data. KRAS G12C is very common. I think this is the first foot in the door to helping patients with this deadly disease. Congrats to the investigators and thanks to the patients!